Trial · NCT02317744
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo
NCT02317744, Not applicable, Completed, Yale University; results first posted 2017-12-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo. Trials, record NCT02317744. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02317744
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo
- NCT number
- NCT02317744
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 22 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Binge Eating Disorder
- Interventions
- Naltrexone and bupropion combination, Pill Placebo
- First posted
- 2014-12-16
- Last updated
- 2017-12-22
- Results first posted
- 2017-12-22
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Binge Eating Frequency (Continuous) | Post-treatment (at 3 months) | Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). |
| Primary | Binge Eating Frequency (Continuous) | 6 month follow-up (an average of 6 months following treatment) | Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). |
| Secondary | Body Mass Index (BMI) | Post-treatment (at 3 months) | BMI is calculated using measured height and weight. |
| Secondary | Body Mass Index (BMI) | 6 month follow-up (an average of 6 months following treatment) | BMI is calculated using measured height and weight. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Binge Eating Frequency (Continuous) | Post-treatment (at 3 months) | binge eating days (out of 28) | MEAN | |
| PRIMARY | Binge Eating Frequency (Continuous) | 6 month follow-up (an average of 6 months following treatment) | binge eating days (out of 28) | MEAN | |
| SECONDARY | Body Mass Index (BMI) | Post-treatment (at 3 months) | kg/m^2 | MEAN | |
| SECONDARY | Body Mass Index (BMI) | 6 month follow-up (an average of 6 months following treatment) | kg/m^2 | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Binge Eating Frequency (Continuous) | Naltrexone/ Bupropion Combination | 4.4 | Full Range 0 to 28 | binge eating days (out of 28) | |
| Binge Eating Frequency (Continuous) | Pill Placebo | 3.0 | Full Range 0 to 16 | binge eating days (out of 28) | |
| Binge Eating Frequency (Continuous) | Naltrexone/ Bupropion Combination | 5.4 | Full Range 0 to 25 | binge eating days (out of 28) | |
| Binge Eating Frequency (Continuous) | Pill Placebo | 2.9 | Full Range 0 to 14 | binge eating days (out of 28) | |
| Body Mass Index (BMI) | Naltrexone/ Bupropion Combination | 34.5 | Full Range 29 to 48 | kg/m^2 | |
| Body Mass Index (BMI) | Pill Placebo | 39.7 | Full Range 32 to 47 | kg/m^2 | |
| Body Mass Index (BMI) | Naltrexone/ Bupropion Combination | 35.9 | Full Range 28 to 48 | kg/m^2 | |
| Body Mass Index (BMI) | Pill Placebo | 40.3 | Full Range 34 to 45 | kg/m^2 |
Source ClinicalTrials.gov
Participant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Naltrexone/ Bupropion Combination | 12 | |
| Overall Study | STARTED | Pill Placebo | 10 | |
| Overall Study | Completed Treatment | Naltrexone/ Bupropion Combination | 10 | |
| Overall Study | Completed Treatment | Pill Placebo | 7 | |
| Overall Study | COMPLETED | Naltrexone/ Bupropion Combination | 11 | |
| Overall Study | COMPLETED | Pill Placebo | 8 | |
| Overall Study | NOT COMPLETED | Naltrexone/ Bupropion Combination | 1 | |
| Overall Study | NOT COMPLETED | Pill Placebo | 2 |
Source ClinicalTrials.gov
Adverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anxiety | Psychiatric disorders | Naltrexone/ Bupropion Combination | 3 | 11 | |
| other | Anxiety | Psychiatric disorders | Pill Placebo | 5 | 8 | |
| other | Vomiting | Gastrointestinal disorders | Naltrexone/ Bupropion Combination | 3 | 11 | |
| other | Vomiting | Gastrointestinal disorders | Pill Placebo | 0 | 8 | |
| other | Constipation | Gastrointestinal disorders | Naltrexone/ Bupropion Combination | 2 | 11 | |
| other | Constipation | Gastrointestinal disorders | Pill Placebo | 1 | 8 | |
| other | Diarrhea | Gastrointestinal disorders | Naltrexone/ Bupropion Combination | 2 | 11 | |
| other | Diarrhea | Gastrointestinal disorders | Pill Placebo | 2 | 8 | |
| other | Dizziness | General disorders | Naltrexone/ Bupropion Combination | 5 | 11 | |
| other | Dizziness | General disorders | Pill Placebo | 1 | 8 |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Naltrexone/ Bupropion Combination | 0 | 11 |
| Total, all-cause mortality | Pill Placebo | 0 | 8 |
| Total, other adverse events | Naltrexone/ Bupropion Combination | 11 | 11 |
| Total, other adverse events | Pill Placebo | 5 | 8 |
| Total, serious adverse events | Naltrexone/ Bupropion Combination | 0 | 11 |
| Total, serious adverse events | Pill Placebo | 0 | 8 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33218742 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Naltrexone/ Bupropion Combination vs Pill Placebo: deaths from any cause | Trial comparisons |
| Naltrexone/ Bupropion Combination vs Pill Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02317744
GET https://conductscience.org/api/trials/v1/NCT02317744/events?page=2